国产复方倍他米松注射液局部注射治疗神经性皮炎的多中心对照临床研究

目的 评价国产复方倍他米松注射液局部单次注射治疗神经性皮炎的安全性和疗效.方法 采用多中心、随机盲法、阳性药物平行对照的临床研究.受试者分别接受国产和进口复方倍他米松注射液治疗.在治疗前(D0)、治疗中(D14)及治疗后(D28)分别对各观察指标进行评估记录.结果 共入组病例144例,完成试验139例,其中对照组68例,试验组71例.疗后4周FAS分析显示,对照组有效率为86.11%,试验组为86.11%(χ2=0.00,P>0.05).痊愈率对照组为59.72%,试验组为54.17%(χ2=0.45,P>0.05).治疗结束时无严重不良事件出现,仅对照组有1例发生轻度皮肤萎缩,经随访自行好转,两组不良反应发生率差异无统计学意义(P>0.05).结论 国产复方倍他米松注射液治疗神经性皮炎安全有效.

Abstract：

Objective To evaluate the safety and efficacy of single and local use of a China-made compound betamethasone injection in the treatment of lichen simplex chronicus. Methods A multi-center,randomized, parallel controlled study was conducted. Patients with lichen simplex chronicus were divided into test and control groups to receive a single dose of intralesional compound betamethasone injection made in China or Schering-Plough Labo N.V. Belgium. Patients were visited for the evaluation of efficacy and safety of the China-made injection at the beginning of the treatment (DO), on week 2 (D14) and 4 (D28) after the initiation of treatment. Results A total of 144 patients were enrolled, among which, 68 in the control group and 71 in the test group completed the trial. FAS analysis on week 4 revealed that the response rate and healing rate were 86.11% and 59.72% in the control group, respectively, 86.11% and 54.17% in the test group, respectively (χ2=0.00,0.45,respectively,both P>0.05).There was no severe adverse event in either group after the treatment, and only mild atrophoderma occurred in one patient in the control group, which was improved spontaneously within several weeks of follow-up. There was no statistically significant difference in the occurrence of side reactions between the two groups (P> 0.05). Conclusion The China-made compound betamethasone injection is effective and safe for the treatment of lichen simplex chronicus.     

长脉冲1064nm Nd:YAG激光治疗兔耳增生性瘢痕的实验研究

目的 通过建立兔耳增生性瘢痕模型,评价长脉冲1064 nm激光治疗增生性瘢痕的疗效.方法 选用新西兰长耳白兔10只,雌雄各半,体质量2.0～2.5 kg.在所有兔耳腹侧面建立增生性瘢痕模型,每只兔耳4处1.5 cm x 1.5 cm正方形造模.10只兔子共80个创面形成增生性瘢痕74处,将左侧和右侧兔耳增生性瘢痕块分为对照组和治疗组,治疗组应用长脉冲1064 nm激光照射,对照组未予治疗.30 d后观察实验组及对照组瘢痕的颜色、质地;彩色超声测量瘢痕厚度;瘢痕取材,HE染色和CD31免疫组化染色,记数瘢痕成纤维细胞密度和微血管密度;Masson染色观察胶原纤维.结果 激光治疗组较对照组瘢痕颜色变浅,质地变柔软,瘢痕厚度变薄,对照组搬痕的平均厚度为3.089 mill,治疗组为2.137 mm,两组比较,t=5.72,P<0.01.对照组血管密度均值为68.056个/mm2,治疗组为38.333个/mm2,两组比较,t=4.93,P<0.01,治疗组血管密度较对照组明显降低.成纤维细胞数量均值对照组为355.000个/mm2,治疗组为166.940个/mm2,两组比较,t=13.36,P<0.01,治疗组成纤维细胞数量明显减少.Masson染色观察对照组胶原纤维排列紊乱,治疗组胶原纤维排列疏松,规则.结论 长脉冲1064 nm激光可以促进早期增生性瘢痕消退,对瘢痕增生具有抑制作用.

Abstract：

Objective To evaluate the therapeutic effect of long-pulsed Nd:YAG 1064 laser on hyperplastic scars by using a rabbit ear model.Methods Five female and five male New Zealand long-ear white rabbits weighting 2.0-2.5 kg were used in this experiment.Four square full-thickness skin wounds sized 1.5 cm x1.5 cm were created on the ventral surface of each ear to develop a model of hyperplastic scar.Finally,a total of 74 hyperplastic scars developed on the 80 wounds,and the scars on the left and right ears served as the control (unirradiated) and treatment (irradiated with long-pulsed 1064 nm Nd:YAG laser) group,respectively.After 30 days of irradiation,the color and texture of scars were observed and the scar thickness was measured by color Doppler ultrasonogTaphy.Then,the scars were harvested followed by the analysis of density of fibroblasts and microvessels as well as the changes in collagen fibers in scars by HE staining,CD31 staining and Masson staining,respectively.Results A decrease was observed in the color,hardness and thickness of scars in the irradiated ears compared with the unirradiated ears.The average thickness of scars,microvessel density and fibroblast density in scars were significantly lower in the treatment group than in the control group(2.137vs.3.089 am,t=5.72,P<0.01;38.333/mm2vs.68.056/mm2,t=4.93,P<0.01;166.940/mm2vs.355.000/mm2,t=13.36.P<0.01).Masson staining revealed a disorganized arrangement of collagen fibers in the control group but a sparse and regular alignment in the treatment group.Conclusion Long-pulsed 1064 nm Nd:YAG laser may promote the shrinkage and suppress the hyperplasia of scars.     

CO2激光联合5-氨基酮戊酸光动力疗法治疗尖锐湿疣疗效观察

Objective To evaluate the effect of CO2 laser in combination with 5-aminolevulinic acidphotodynamic therapy (ALA-PDT) on clearance and recurrence of condyloma acuminatum (CA). Methods A total of 124 patients with CA were randomly and equally divided into two groups to be treated with CO2 laser plus ALA-PDT (test group) or CO2 laser only (control group). Results The cure rate and recurrence rate were 90.6% (58/62) and 9.4% (4/62), respectively in the test group, 76.7% (46/62) and 23.3% (16/62)respectively in the control group. There was a statistical difference in the cure rate and recurrence rate between he two groups (both P ＜ 0.05). Conclusion CO2 laser in combination with ALA-PDT is superior to CO2 laser alone in the treatment of CA.     

CO2激光联合5-氨基酮戊酸光动力疗法治疗尖锐湿疣疗效观察

Objective To evaluate the effect of CO2 laser in combination with 5-aminolevulinic acidphotodynamic therapy (ALA-PDT) on clearance and recurrence of condyloma acuminatum (CA). Methods A total of 124 patients with CA were randomly and equally divided into two groups to be treated with CO2 laser plus ALA-PDT (test group) or CO2 laser only (control group). Results The cure rate and recurrence rate were 90.6% (58/62) and 9.4% (4/62), respectively in the test group, 76.7% (46/62) and 23.3% (16/62)respectively in the control group. There was a statistical difference in the cure rate and recurrence rate between he two groups (both P ＜ 0.05). Conclusion CO2 laser in combination with ALA-PDT is superior to CO2 laser alone in the treatment of CA.     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

晚期糖基化终末产物及其受体在瘢痕疙瘩中的表达

目的 研究晚期糖基化终末产物（AGE）及其受体（AGER）在瘢痕疙瘩中的表达。方法 瘢痕疙瘩、增生性瘢痕和正常人群血清、皮肤组织标本各20份,以荧光分光光度计检测三组人群血清中AGE含量,分别采用免疫组化法、Western印迹分析检测三组人群皮肤组织标本中AGE和AGER表达情况。结果 瘢痕疙瘩组血清中AGE含量为（0.713 ± 0.098） AU/ml,增生性瘢痕组为（0.699 ± 0.077） AU/ml,明显高于正常人群组（0.179 ± 0.056） AU/ml,三组差异有统计学意义（F = 283.82,P < 0.01）。免疫组化显示,AGE、AGER在瘢痕疙瘩、增生性瘢痕皮肤组织标本中表达阳性,正常人群组织表达则为阴性。Western印迹检测显示,瘢痕疙瘩、增生性瘢痕组织中AGE和AGER蛋白表达均明显高于正常人群,差异有统计学意义（F值分别为18.04、42.80,P < 0.05）,而瘢痕疙瘩和增生性瘢痕组之间差异无统计学意义（P > 0.05）。结论 AGE和AGER在瘢痕疙瘩中表达升高,在其发病过程中可能发挥一定的促进作用。     

得宝松局封联合咪喹莫特乳膏治疗瘢痕疙瘩疗效评价

目的:评价复方倍他米松注射液皮损内注射联合5%咪喹莫特乳膏外涂治疗瘢痕疙瘩的疗效。方法:将患者随机分为两组,治疗组给予复方倍他米松注射液皮损内注射,每3周1次,共3次。同时给予隔日外涂5%咪喹莫特乳膏,连续3个月;对照组单纯给予复方倍他米松注射液皮损内注射。两组患者均于疗程结束后6个月评价疗效和复发。结果:治疗组有效率93.55%,对照组有效率70.37%,复发率治疗组低于对照组,差异有显著性意义,不良反应轻微。结论:复方倍他米松注射液皮损内注射联合5%咪喹莫特乳膏外涂治疗瘢痕疙瘩安全、有效。     

无针注射器瘢痕疙瘩内注射糖皮质激素的疗效研究

目的 比较无针注射器与普通注射器瘢痕疙瘩内注射糖皮质激素的疗效。 方法 瘢痕疙瘩患者60例分为无针注射器组31例,普通注射器组29例。两组均使用复方倍他米松注射液进行皮损内注射,注射剂量0.2 ml/cm3,均为3周1次,连续3次。收集入组病例每次治疗前后参数数据、不良反应观察指标和每次治疗前后临床照片。采用Mann-Whitney检验、χ2检验等对两组参数数据进行统计学分析。 结果 第1次和第2次注射时间、第1次注射后疼痛时间Mann-Whitney检验U值分别为299.000、773.500、730.000,P值分别为0.000、0.000、0.003,其差异有统计学意义。3次治疗后体积、高度、硬度、痛觉、痒觉、外观评价、注射点数Mann-Whitney检验U值分别为295.000、336.500、264.000、464.000、451.500、308.000、233.500,P值分别为0.001、0.007、0.000、0.041、0.043、0.003、0.001,其差异均有统计学意义。两组3次治疗后不良反应发生率比较,差异无统计学意义（均P > 0.05）。无针注射器组皮损反跳临界时间11.8 d（95% CI：10.96 ~ 12.6 d）比普通注射器组皮损反跳临界时间21.2 d（95% CI：13.96 ~ 28.45 d）短。 结论 无针注射器治疗瘢痕疙瘩与普通注射器相比,疗效好,又可以降低注射难度,提高患者治疗依从性。     

Intralesional 5-fluorouracil in the treatment of keloid scars

Two patients with keloid scars are described. The first patient presented with extensive keloid scarring on both cheeks secondary to acne. The second patient developed a keloid scar on her chest following excision of a mole. Both patients' scars were diagnosed clinically and treated with fortnightly injections of a mixture of 5-fluorouracil and betamethasone acetate and betamethasone sodium phosphate. At each injection session up to 1.6 mL of 5-fluorouracil at a concentration of 500 mg/10 mL and 0.4 mL of betamethasone acetate and betamethasone sodium phosphate (as betamethasone acetate 3 mg in suspension and betamethasone sodium phosphate 3.9 mg in solution) were used. Multiple treatments were required to obtain resolution of the keloid scars. Improvement was maintained in both patients at 1 year post treatment.     

UVA1联合复方倍他米松注射液治疗瘢痕疙瘩疗效观察

目的探讨长波紫外线1(ultraviolet A1,UVA1)照射联合复方倍他米松注射液治疗瘢痕疙瘩的疗效。方法实验组予复方倍他米松注射液0.10~0.15mL/cm2于瘢痕皮损内注射,1次/月,同时予以UVA1照射,隔日1次,初始剂量46.8J/cm2,最大剂量93.6J/cm2;对照组仅予复方倍他米松注射液治疗。两组均连续治疗2~4月,治疗结束后10~12周时评价疗效。共随访9个月。结果治疗组总有效率(78.13%)显著高于对照组(62.16%),差异有统计学意义(P=0.043)。但治疗组有6例在大剂量照射时(78J/cm2)出现局部红肿等不良反应,而对照组无该现象。结论 UVA1联合复方倍他米松注射液治疗瘢痕疙瘩能显著促进其临床症状改善,但高剂量时可能具有一定的皮肤刺激反应。     

复方倍他米松穴位注射联合中药浸泡治疗掌跖角化性湿疹的临床观察

目的探讨复方倍他米松穴位注射联合中药浸泡治疗掌跖角化性湿疹的疗效。方法将82例掌跖角化性湿疹患者随机分为治疗组(42例)和对照组(40例)。治疗组采用复方倍他米松1mL稀释于2%利多卡因中穴位注射,每穴位1mL,每2周1次,共2次;同时给予中药浸泡每日1剂,30min/次,2次/d,共4周。对照组外用卤米松乳膏和尿素霜2次/d,连用4周。结果治疗组有效率85.71%,痊愈率59.52%,对照组分别为55.00%和17.50%,两组比较差异均有统计学意义(P均<0.01)。3个月后,治疗组复发率为12.00%,对照组为57.14%,两组比较差异有统计学意义(P<0.05)。结论使用复方倍他米松穴位注射联合中药浸泡治疗掌跖角化性湿疹疗效高、复发率低。     

两种糖皮质激素注射液皮损内注射治疗活动期斑秃的临床疗效观察

目的 比较复方倍他米松注射液和醋酸曲安奈德注射液皮损内注射治疗活动期斑秃的临床疗效。方法 将160例活动期斑秃患者随机分成两组,治疗组100例、对照组60例,治疗组用复方倍他米松注射液皮损内注射,对照组用醋酸曲安奈德注射液皮损内注射,每3周1次,12周后观察结果。结果 治疗12周后治疗组痊愈60例（60.0%）,显效32例（32.0%）,总有效率92.0%;对照组痊愈25例（41.7%）,显效19例（31.67%）,总有效率73.3%;治疗组有效率和痊愈率显著高于对照组（χ2值分别为10.25和5.06,P ＜ 0.01和 ＜ 0.05）。治疗组出现局部头皮萎缩8例（8%）,局部毛囊炎8例（8%）;对照组出现局部头皮萎缩9例（15%）,局部毛囊炎3例（5%）,两组不良反应发生率比较,差异无统计学意义（P ＞ 0.05）。结论复方倍他米松注射液皮损内注射治疗活动期斑秃疗效显著。     

The use of silicone gel in the treatment of fresh surgical scars: a randomized study

Aim.  To evaluate the effectiveness of a silicone gel in treating surgical wounds compared with a control group of the same phenotype and same scar site for which a placebo was advised.
Methods.  This was a randomized controlled trial, carried out in a dermatology department of a university hospital. In total, we studied 110 patients (55 men, 55 women) who had undergone outpatient surgery at the Department of Dermatology, University of Florence, between May and July 2005. The patients were divided into two groups: a treatment group (group A) and a control group (group B). Subjects ( n  = 65) in group A were prescribed silicone gel to be applied to the wound twice a day for 60 days after the removal of stitches. Subjects ( n  = 45) in group B were prescribed the use of zinc oxide cream. All subjects, in both study and control groups, were examined by the same dermatologists every month for 3 months after surgery, then every 2 months for a total follow-up of 8 months from the date of surgery.
Results.  In the treatment group, only 18 patients (27%) had formation of a nonphysiological scar: diastasic scar in 10 patients (15%), hypertrophic scar in 6 (9%) and atrophic scar in 2 (3%). No keloid scars were recorded. In the control group, 25 (55%) had an altered scar: keloid scars in 5 patients (11%), hypertrophic scar in 10 (22%), diastasic scar in 8 (18%) and atrophic scar in 2 (4%).
Conclusions.  The results of this study indicate that silicone gel is able to reduce the formation of keloid and hypertrophic scars and the signs/symptoms associated with the healing process (paraesthesia, pulling sensation, alterations in colour).     

Expression of p53 family in scars

BACKGROUND: There have been some reports on the relationship between p53 and keloid formation. However, there have been no studies comparing the p53 expression among scars in various stages of maturity. However, p63 and p73 have been identified as p53-related genes and have been found to be similar to p53 in their structures and functions and these proteins have also been suggested to relate to scar formation. OBJECTIVE: We investigate the expression of three proteins of the p53 family in scars with various clinical manifestations and discuss the shared features and differences of these proteins. METHODS: Forty untreated scar lesions consisting of keloids, hypertrophic scars, and atrophic scars were prepared for investigation. We detected the expression of p53, p63 and p73 proteins using Western blot analysis and histopathological study in each sample. RESULTS: The 40 lesions were divided into four groups according to their clinical manifestations: keloid (Group A), red hypertrophic scar (Group B), white and hard hypertrophic scar (Group C), atrophic white scar (Group D). In Groups A and B, the histopathological findings demonstrated increased fibroblasts, capillary vessels and infiltration of inflammatory cells. In Group C, most of these changes decreased but proliferation of collagen fibers was evident. In Group D, the degree of proliferation of collagen fibers was much less and capillary vessels and infiltration of inflammatory cells were not evident. The levels of p53 protein elevated in Groups A, B and C and were higher in order of Groups A, B and C. In Group D, the level of p53 was almost the same as that of the control. The level of p63 protein was almost the same as that of the control in all groups. The level of p73 protein was elevated only in Group C. CONCLUSION: The p53 family members behave in a different manner in various scar tissues. It is suggested that these proteins play different roles in scar formation and the development of unfavorable scars.